Business Context and Reporting Period
Company: BioMarin Pharmaceutical Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 16, 2026
Subject: Discontinuation of dosing and enrollment in specific Phase 2 clinical trials for the drug VOXZOGO.
Key Financial Metrics
This filing is a Current Report (Item 8.01 Other Events) and does not contain financial statements. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Operational Events
- Discontinued Trials: BioMarin announced the discontinuation of dosing and enrollment in Phase 2 trials for VOXZOGO in patients with Turner Syndrome, SHOX-deficiency, and Aggrecan (ACAN)-deficiency.
- Cause: The decision follows the occurrence of several slipped capital femoral epiphysis (SCFE) events in two ongoing investigator-sponsored trials.
- Safety Context:
- SCFE events have not been observed in BioMarin's Phase 2 trials for these specific conditions.
- No SCFE cases have been observed in over 5,000 infants and children receiving VOXZOGO for achondroplasia (10+ years of research, 10,000+ patient-years).
- No cases observed in clinical trials for hypochondroplasia.
- Continuing Trials: Phase 2 CANOPY trials for VOXZOGO in children with Noonan syndrome and Idiopathic Short Stature (ISS) without ACAN-deficiency (approx. 95% of ISS trial enrollment) will continue as planned.
Guidance, Outlook, and Risks
Management Commentary: The company is utilizing its investor relations website for material non-public information disclosures under Regulation FD.
Forward-Looking Statements: The filing includes predictions regarding the discontinuation of specific trials and the continuation of others. Management notes that actual results may differ materially due to risks including clinical trial results, regulatory decisions, and factors detailed in the 2025 Form 10-K.
Risks: The primary risk highlighted is the safety signal (SCFE events) impacting the development timeline for specific indications of VOXZOGO.
Investor Verification Checklist
- Verify the specific number and nature of SCFE events in the investigator-sponsored trials mentioned.
- Confirm the impact of this discontinuation on the projected revenue timeline for VOXZOGO in Turner Syndrome, SHOX-deficiency, and ACAN-deficiency.
- Review the "Risk Factors" section of the most recent Form 10-K for updated safety profiles regarding VOXZOGO.
- Monitor future communications regarding the status of the continuing Noonan syndrome and ISS trials.